Report
Autolus FIRST LOOK: MHRA certification for manufacturing site
Autolus' manufacturing site, the Nucleus, has obtained MIA and GMP certification from the MHRA, enabling production of global commercial and clinical product supply. We estimate the site to have a capacity of 2,000+ batches per year, sufficient to cover the company's launch in r/r ALL and beyond, while targeting a vein-to-delivery time of 16 days at launch. With ample capacity at launch, we do not expect Autolus to run into the manufacturing or supply issues experienced by other companies during the first CAR-T launches. We reiterate our $ 11 TP and Buy rating.
Underlying
Autolus Therapeutics ADS
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Jacob Mekhael
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.